Press Releases

Date Title and Summary View
Toggle Summary Revance Therapeutics Releases First Quarter 2014 Financial Results
Reiterates Full-Year Financial Guidance
View HTML
Toggle Summary Revance Appoints Mark A. Prygocki to Its Board of Directors
NEWARK, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Mark A. Prygocki has been appointed to its Board of
View HTML
Toggle Summary Revance Therapeutics to Release First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014
NEWARK, Calif. , April 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release first quarter 2014 financial
View HTML
Toggle Summary Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines
Median Duration of 7.3 Months
View HTML
Toggle Summary Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes
NEWARK, Calif., March 31, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
View HTML
Toggle Summary Revance Therapeutics Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
NEWARK, Calif., March 26, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three and twelve months ended December 31, 2013. Recent Accomplishments and Progress Toward Milestones Closing of the Company's initial public offering (IPO) in
View HTML
Toggle Summary Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March 26, 2014
NEWARK, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release fourth quarter and full year
View HTML
Toggle Summary Revance to Add Angus C. Russell as Chairman to Its Board of Directors
NEWARK, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Angus C. Russell has been appointed as Chairman to its
View HTML
Toggle Summary Revance Therapeutics, Inc. Announces Participation in Cowen 34th Annual Health Care Conference
NEWARK, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen 34th Annual Health Care Conference in Boston. Revance management is scheduled to present on Wednesday, March 5, 2014 at 9:20 am
View HTML
Toggle Summary Revance Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
Gross Proceeds of Offering Total $110 Million
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools